Astal Laboratories Ltd

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, reported net profit of ₹2.36 crores for Q3 FY26 (October-December 2025), reflecting an 8.53% decline quarter-on-quarter but a modest 5.22% decline year-on-year. Despite impressive top-line expansion, the company's profitability metrics reveal a concerning deterioration in operational efficiency that has sent the stock into bearish territory, trading at ₹77.60 as of February 17, 2026—down 24.81% from its 52-week high of ₹103.20.

Astal Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in its quality metrics and financial trends despite valuation concerns and recent price weakness. The revised assessment follows a comprehensive review of four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Astal Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While key metrics such as return on equity (ROE) and return on capital employed (ROCE) remain modest, improvements in sales and earnings growth alongside low debt levels have contributed to this upgrade. However, investors should weigh these positives against the company’s middling profitability ratios and recent share price underperformance relative to the Sensex.

Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Astal Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 21 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Astal Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a deterioration in the stock’s medium to long-term momentum, raising concerns among investors about potential weakness ahead.

Astal Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators, valuation metrics, financial trends, and overall quality. This upgrade, effective from 16 January 2026, comes amid a strong market performance and robust quarterly results, signalling a more favourable outlook for the trading and distributors sector player.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 29 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 12 January 2026, providing investors with the latest perspective on the company’s position.

Astal Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a deterioration in technical indicators despite robust financial performance and attractive valuation metrics. The latest assessment by MarketsMOJO reflects a nuanced view of the company’s quality, valuation, financial trend, and technical outlook as of 29 Dec 2025.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the most recent insights into its performance and outlook.

Astal Lab, a microcap player in the Trading & Distributors sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and evolving financial indicators.